Table 1 Clinicopathological and molecular features of NSCLC consecutively evaluated for pan-TRK (n = 147).

Variable	Parameter	n	%
	Mean (min–max)	64.0 (32.0–94.0)
Age (year)	≤ 64	77	52.4
Age (year)	> 64	70	47.6
Sex	Male	83	56.5
Sex	Female	64	43.5
Smoking	Never	37	25.2
	Quitter	49	33.3
	Current	57	38.8
	No information	4	2.7
Loss of weight^a	No	77	52.4
	≤ 10%	23	15.6
	> 10%	29	19.8
	No information	18	12.2
ECOG PS at diagnosis	0	27	18.4
	1	79	53.7
	2	22	15.0
	3	10	6.8
	No information	9	6.1
Histology	Adenocarcinoma	109	74.1
	Squamous cell	7	4.8
	NSCLC^b	31	21.1
Stage at diagnosis^c	I/II	28	19.0
	III	26	17.7
	IV	83	56.5
	No information	10	6.8
Metastasis at diagnosis	No	54	36.7
	Yes, CNS	24	16.3
	Yes, Others	59	40.2
	No information	10	6.8
pan-TRK IHC	Negative	135	91.8
pan-TRK IHC	Positive	12	8.2
EGFR mutations	Wild-type	119	81.0
	Mutated	24	16.3
	No information	4	2.7
KRAS mutations	Wild-type	99	67.3
	Mutated	36	24.5
	No information	12	8.2
ALK fusions	Wild-type	130	88.4
	Mutated	7	4.8
	No information	10	6.8
Vital status	Alive	92	62.6
	Deceased	54	36.7
	No information	1	0.7

n, number of patients; ECOG PS (Eastern Cooperative Oncology Group Performance Status); NSCLC, Non-small cell lung cancer; ^aprior to 6 months to diagnosis; ^bincluding the following histologies: NSCLC NOS (not otherwise specified), neuroendocrine large cell carcinoma, adenosquamous carcinoma, ^caccording to AJCC 8th edition; ^dpan-TRK IHC (immunohistochemistry).

Quick links

Search